These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

801 related items for PubMed ID: 29247711

  • 21. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q.
    Cancer Lett; 2013 Dec 01; 341(2):231-9. PubMed ID: 23962558
    [Abstract] [Full Text] [Related]

  • 22. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK, Ip CK, Mak AS, Lai HC, Wong AS.
    Oncogene; 2013 May 30; 32(22):2767-81. PubMed ID: 22797058
    [Abstract] [Full Text] [Related]

  • 23. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
    Wen JF, Jiang YQ, Li C, Dai XK, Wu T, Yin WZ.
    Cancer Biomark; 2020 May 30; 28(2):231-246. PubMed ID: 32508321
    [Abstract] [Full Text] [Related]

  • 24. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z.
    Cancer Biol Ther; 2010 Oct 15; 10(8):788-95. PubMed ID: 20686362
    [Abstract] [Full Text] [Related]

  • 25. Role of autophagy in cisplatin resistance in ovarian cancer cells.
    Wang J, Wu GS.
    J Biol Chem; 2014 Jun 13; 289(24):17163-73. PubMed ID: 24794870
    [Abstract] [Full Text] [Related]

  • 26. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
    Yu T, Yang Y, Zhang J, He H, Ren X.
    Eur J Pharm Biopharm; 2015 Apr 13; 91():103-10. PubMed ID: 25668779
    [Abstract] [Full Text] [Related]

  • 27. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H, Wei W, Sun Y, Gao J, Wang Q, Zheng J.
    DNA Cell Biol; 2015 Jan 13; 34(1):55-62. PubMed ID: 25211326
    [Abstract] [Full Text] [Related]

  • 28. Euxanthone inhibits glycolysis and triggers mitochondria-mediated apoptosis by targeting hexokinase 2 in epithelial ovarian cancer.
    Zou J, Wang Y, Liu M, Huang X, Zheng W, Gao Q, Wang H.
    Cell Biochem Funct; 2018 Aug 13; 36(6):303-311. PubMed ID: 29984416
    [Abstract] [Full Text] [Related]

  • 29. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
    Wang Y, Mao H, Hao Q, Wang Y, Yang Y, Shen L, Huang S, Liu P.
    Regul Pept; 2012 Oct 10; 178(1-3):36-42. PubMed ID: 22759793
    [Abstract] [Full Text] [Related]

  • 30. ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy.
    Meng J, Liu K, Shao Y, Feng X, Ji Z, Chang B, Wang Y, Xu L, Yang G.
    Cell Death Dis; 2020 Feb 20; 11(2):137. PubMed ID: 32080166
    [Abstract] [Full Text] [Related]

  • 31. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
    Yan C, Yang F, Zhou C, Chen X, Han X, Liu X, Ma H, Zheng W.
    Int J Clin Exp Pathol; 2015 Feb 20; 8(3):2710-8. PubMed ID: 26045776
    [Abstract] [Full Text] [Related]

  • 32. Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.
    Gocher AM, Azabdaftari G, Euscher LM, Dai S, Karacosta LG, Franke TF, Edelman AM.
    J Biol Chem; 2017 Aug 25; 292(34):14188-14204. PubMed ID: 28634229
    [Abstract] [Full Text] [Related]

  • 33. Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer.
    Hwang JR, Kim WY, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim MS, Kim JH, Paik ES, Lee YY, Han HD, Lee JW.
    Cell Death Dis; 2020 Dec 04; 11(12):1034. PubMed ID: 33277461
    [Abstract] [Full Text] [Related]

  • 34. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR, Schorl C, Yano N, Romano N, Kim KK, Singh RK, Moore RG.
    J Ovarian Res; 2016 May 17; 9(1):28. PubMed ID: 27184254
    [Abstract] [Full Text] [Related]

  • 35. Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway.
    Wu J, Zhang X, Wang Y, Sun Q, Chen M, Liu S, Zou X.
    Oncol Rep; 2018 Mar 17; 39(3):1181-1190. PubMed ID: 29286170
    [Abstract] [Full Text] [Related]

  • 36. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H, Shi C, Yan Z, Li H.
    Drug Des Devel Ther; 2015 Mar 17; 9():3183-90. PubMed ID: 26124641
    [Abstract] [Full Text] [Related]

  • 37. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
    Ai Z, Lu Y, Qiu S, Fan Z.
    Cancer Lett; 2016 Apr 01; 373(1):36-44. PubMed ID: 26801746
    [Abstract] [Full Text] [Related]

  • 38. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S, Fu GB, Tao Z, OuYang J, Kong F, Jiang BH, Wan X, Chen K.
    Oncotarget; 2015 Sep 22; 6(28):26457-71. PubMed ID: 26238185
    [Abstract] [Full Text] [Related]

  • 39. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
    Ma Y, Cao H, Lou S, Shao X, Lv W, Qi X, Liu Y, Ying M, He Q, Yang X.
    J Mol Med (Berl); 2015 Apr 22; 93(4):427-38. PubMed ID: 25411027
    [Abstract] [Full Text] [Related]

  • 40. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X, Zhang Q, Yang X, Zhao M, Yang T, Yao A, Tian X.
    Biochem Biophys Res Commun; 2019 Apr 16; 511(4):719-724. PubMed ID: 30827507
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.